However, there have been limited studies on whether TP53-mutated ctDNA in NHL can be measured by ddPCR and used as a suitable biomarker for MRD tracking and the further stratification of patients who receive CAR T cell therapy. This evidence concerns the gene TP53 and non-Hodgkin lymphoma.